Perimenopause, HRT and Your Eyes

Key overview

  • Androgens influence meibomian gland function directly, and falling androgen levels are the likely driver.
  • Symptoms commonly begin in perimenopause, years before periods stop, which is why the connection is often missed.
  • The evidence on HRT and dry eye is genuinely mixed. Some data associates oestrogen-only therapy with worse symptoms.
  • Never start, stop or change hormone therapy because of your eyes. That decision belongs with your prescriber.

Dry eye becomes markedly more common around and after menopause, and the connection is frequently missed because the eye symptoms often arrive before the symptoms people associate with the transition.

The mechanism

Meibomian glands are sebaceous glands, and sebaceous glands throughout the body are androgen-sensitive. Androgens — present in women at lower levels than men but physiologically important — support meibomian gland function and the quality of what they secrete.

Androgen levels decline through perimenopause and after. The working explanation for the rise in dry eye at this stage is that reduced androgen support degrades gland function, producing the evaporative picture: burning that worsens through the day, watering despite dryness, an unstable tear film.

This is also thought to be part of why dry eye is more common in women generally, not only after menopause.

Why it starts earlier than people expect

Perimenopause can run for several years before periods stop, with hormonal fluctuation well underway. Eye symptoms in that window are often attributed to screens, age or tiredness, and the pattern only becomes obvious in retrospect.

If you are in your forties with new or worsening dry eye alongside sleep disturbance, mood changes or irregular cycles, it is worth mentioning the eyes to whoever is managing the rest — and worth mentioning the hormonal context to your optometrist. Neither will necessarily join those dots unprompted.

What the evidence says about HRT

This is where honesty matters more than a clean answer. The evidence on hormone therapy and dry eye is mixed and does not support a simple expectation of improvement.

Some data has associated oestrogen-only therapy with a higher prevalence of dry eye rather than a lower one, which is counterintuitive if you assume replacing hormones restores gland function. Combined therapy appears more equivocal. The picture is complicated by the fact that the androgen decline may be the more relevant variable, and standard HRT is not principally an androgen replacement.

The practical upshot: hormone therapy may improve your dry eye, may do nothing, and may coincide with worsening. If you are starting or changing HRT, it is worth noting where your eyes are beforehand so you can tell.

What not to do

Do not start, stop, or alter hormone therapy because of your eyes. HRT decisions are made on a much broader set of considerations — bone density, cardiovascular risk, vasomotor symptoms, individual history — and dry eye is a minor input among them. That decision belongs with the prescriber who holds the whole picture.

Equally, do not let an eye symptom go untreated on the basis that it is hormonal and therefore fixed. Hormonally driven dry eye responds to the same treatment as any other evaporative dry eye.

What does help

The mechanism is glandular, so the treatment is glandular. Heat and expression for the obstruction, lid hygiene for the margin, and omega-3 over a quarter for the composition of the secretion.

The one difference from other causes is persistence. Hormonally driven dry eye tends to be sustained rather than episodic, which makes it a case for maintenance rather than a course of treatment. Our article on menopause and dry eye covers the broader picture.

Where our products fit

A sustained problem calls for a sustained routine rather than an intensive one. The Ongoing Treatment Package is built for that pattern.

Part of our guide to Dry Eye Through Life.